GLP-1 medications can be beneficial for managing Type 2 diabetes and promoting weight loss in some people, but they may not be suitable for everyone
Research from the STEP programme (semaglutide), SCALE studies (liraglutide), and SURMOUNT trials (tirzepatide) consistently demonstrates significant reductions in waist circumference, which correlates with abdominal fat loss
It certainly appears from this data that titration may be an important consideration in incretin use
4, 2020 Food and Drug Administration, FDA Approves First Medication for Obstructive Sleep Apnea, Dec
New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity
This inconsistency may lead to less predictable outcomes over time